KPJ Healthcare Berhad (KLSE:KPJ) Has More To Do To Multiply In Value Going Forward

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. In light of that, when we looked at KPJ Healthcare Berhad (KLSE:KPJ) and its ROCE trend, we weren't exactly thrilled.

Advertisement

What Is Return On Capital Employed (ROCE)?

Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. To calculate this metric for KPJ Healthcare Berhad, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.076 = RM402m ÷ (RM7.0b - RM1.7b) (Based on the trailing twelve months to December 2022).

Therefore, KPJ Healthcare Berhad has an ROCE of 7.6%. On its own, that's a low figure but it's around the 9.3% average generated by the Healthcare industry.

Check out our latest analysis for KPJ Healthcare Berhad

roce
KLSE:KPJ Return on Capital Employed March 7th 2023

In the above chart we have measured KPJ Healthcare Berhad's prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering KPJ Healthcare Berhad here for free.

How Are Returns Trending?

The returns on capital haven't changed much for KPJ Healthcare Berhad in recent years. Over the past five years, ROCE has remained relatively flat at around 7.6% and the business has deployed 68% more capital into its operations. Given the company has increased the amount of capital employed, it appears the investments that have been made simply don't provide a high return on capital.

The Bottom Line

In summary, KPJ Healthcare Berhad has simply been reinvesting capital and generating the same low rate of return as before. And investors may be recognizing these trends since the stock has only returned a total of 33% to shareholders over the last five years. Therefore, if you're looking for a multi-bagger, we'd propose looking at other options.

On a final note, we found 2 warning signs for KPJ Healthcare Berhad (1 makes us a bit uncomfortable) you should be aware of.

While KPJ Healthcare Berhad isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

Valuation is complex, but we're here to simplify it.

Discover if KPJ Healthcare Berhad might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KLSE:KPJ

KPJ Healthcare Berhad

An investment holding company, engages in the operation of specialist hospitals in Malaysia, Thailand, and Australia.

Excellent balance sheet with proven track record.

Advertisement

Weekly Picks

CE
Ceazar
GOAI logo
Ceazar on Eva Live ·

This small cap is building the AI workforce of the future

Fair Value:US$7.4353.2% undervalued
71 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
TR
tripledub
LULU logo
tripledub on lululemon athletica ·

Lululemon Got Boring Right About the Time It Got Cheap. That's Usually the Point

Fair Value:US$22043.1% undervalued
21 users have followed this narrative
6 users have commented on this narrative
23 users have liked this narrative
WO
woodworthfund
KHC logo
woodworthfund on Kraft Heinz ·

Kraft Heinz (KHC): Less Drama, More Ketchup

Fair Value:US$3532.8% undervalued
6 users have followed this narrative
0 users have commented on this narrative
2 users have liked this narrative
CA
Canderous
TAL logo
Canderous on PetroTal ·

Beyond 2026, Beyond a Double

Fair Value:CA$1.8168.5% undervalued
23 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

TR
tripledub
INTU logo
tripledub on Intuit ·

A Wonderful Business at a Not-So-Wonderful Price

Fair Value:US$56031.4% undervalued
26 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
IV
OCI logo
Ivoed on OCI ·

OCI is not being priced on asset value. That is the opportunity.

Fair Value:€6.5643.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
IV
KIN logo
Ivoed on Kinepolis Group ·

Kinepolis Group Set to Achieve 22.52% Revenue Growth Boost, Experts Dream

Fair Value:€4839.0% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.0% undervalued
114 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74018.2% undervalued
39 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$268.6116.8% undervalued
1187 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative